MedWatch

CEO of Novo Holdings: "We have executed the strategy we laid out when I joined"

Following a massive tailwind for Novo Nordisk and solid returns from the stock market, Novo Holdings can now boast of having over EUR 90bn in assets. Still, 2022 will be more difficult, says CEO Kasim Kutay.

Photo: Novo Holdings / PR

When Kasim Kutay took over as CEO of Novo Holdings in 2016, the company’s total assets were value under EUR 40bn. Now, five and a half years later, Novo Holding’s assets have reached a value of over EU90bn.

As CEO, Kutay’s results have benefitted greatly from pharmaceutical firm Novo Nordisk’s success, but Novo Holding has more than just a significantly larger investment portfolio today, as departments from US to China have now been established, with more on the way.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs